Skip to main content

Security report for cslbehring.com

CSL Limited · Healthcare · Australia

Medium risk. 2 critical or high findings in Security headers and SSL/TLS.

Security score

74/100

Risk levelMedium

0–100, higher is better. How it is calculated

CSL Limited is a leading global biotechnology company headquartered in Melbourne, Australia, with a history dating back to 1916. The company specializes in developing and delivering high-quality medicines, including plasma-derived and recombinant therapies, vaccines, and treatments for rare and serious diseases. Its business model focuses on research, development, manufacturing, and global distribution, serving patients in over 100 countries through its subsidiaries CSL Behring, CSL Seqirus, and CSL Vifor. The website reflects a professional and consistent brand presence with comprehensive business descriptions and a clear target audience in the healthcare sector. From a technical perspective, the website employs modern technologies such as Google Tag Manager and OneTrust for cookie consent, indicating a moderate level of digital maturity. The site is mobile-optimized, accessible, and SEO-friendly, although no specific CMS or hosting provider was identified. Performance is moderate, with room for improvement in security headers and explicit privacy policy publication. Security posture is solid with HTTPS enforced and cookie consent mechanisms in place, but the absence of explicit security headers and published security policies or incident response contacts suggests areas for enhancement. The lack of WHOIS data reduces transparency but does not detract significantly from the overall trustworthiness given the strong corporate branding and content. Overall, CSL Limited's website presents a credible and professional digital presence aligned with its global biotechnology leadership. Strategic improvements in security transparency and privacy documentation would further strengthen its security posture and compliance standing.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching cslbehring.com

This scan found 20 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
67
Security headers
50
Email security
60
DNS health
80
Network security
100
GDPR outside view
88
Average
74

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

CSL Limited holds a strong market position as a global biotechnology leader with a diversified portfolio targeting rare and serious diseases, vaccines, and plasma therapies. Its competitive advantage lies in its extensive R&D capabilities, global reach, and operational excellence. The business model is centered on innovation and patient-centric solutions, supported by a robust partnership ecosystem including subsidiaries and related sites such as newsroom.csl.com. Growth indicators include a broad geographic footprint and a history of innovation since 1916. The company targets healthcare providers, patients with rare diseases, and public health sectors worldwide. Strategic observations highlight the importance of maintaining regulatory compliance and enhancing digital security to protect sensitive health data and corporate reputation.

Security posture

The website demonstrates a mature security posture with mandatory HTTPS and cookie consent mechanisms reflecting GDPR awareness. However, the absence of key security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security indicates potential gaps in defense-in-depth strategies. No vulnerabilities or exposed sensitive data were detected in the analyzed content. The lack of published security policies, incident response contacts, or vulnerability disclosure programs suggests limited transparency in security governance. Compliance with privacy regulations is partially evidenced by cookie consent but lacks a visible privacy policy on the analyzed page. Overall, the security maturity is moderate with clear opportunities for improvement in policy publication and technical controls.

Recommendations

  1. Implement and publish comprehensive security headers including Content-Security-Policy, X-Content-Type-Options, X-Frame-Options, and Strict-Transport-Security to enhance browser security.
  2. Publish a clear and accessible privacy policy on the website to improve GDPR compliance and user trust.
  3. Establish and publicize a vulnerability disclosure program or security.txt file to facilitate responsible security reporting.
  4. Provide explicit incident response contact information such as security@ or abuse@ email addresses to improve transparency and readiness.
  5. Regularly audit and update third-party scripts and tracking technologies to minimize privacy risks and ensure compliance.

Contact details published on the site

Addresses
Legal name
CSL Limited
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
CSL Limited
Description
CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since 1916, CSL provides lifesaving products to patients in more than 100 countries.
Key services
plasma-derived therapies, recombinant therapies, influenza vaccines, therapies for rare and serious diseases
Content quality
good
Branding
consistent

Technology

Stack
Google Tag Manager, OneTrust Cookie Consent, Brightcove video player, CSS (Montserrat font), JavaScript
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner implemented

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Marketing tools
OneTrust Cookie Consent
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and content-rich.
  2. Strong branding and consistent corporate identity.
  3. Cookie consent mechanism implemented indicating privacy awareness.
  4. No contact forms detected on the analyzed page; contact info provided via structured data.
  5. No explicit security policies or incident response contacts published.
  6. WHOIS data unavailable, possibly due to registry or privacy protection.
  7. No signs of WAF or content blocking.
  8. No adult or questionable content detected.
Technical notes

Notes

The website uses a modern technology stack including Google Tag Manager for analytics and OneTrust for cookie consent management, indicating a focus on privacy compliance and user tracking control. The use of Brightcove suggests video content capabilities. The site employs the Montserrat font and custom CSS bundles for styling. No CMS or hosting provider was explicitly identified, suggesting a custom or proprietary platform. Performance is moderate with good mobile optimization and accessibility features. Technical debt appears low, but the absence of some security headers and explicit privacy documentation indicates areas for modernization. Overall, the technical infrastructure supports a professional and functional user experience with opportunities for enhanced security and compliance integration.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with cslbehring.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review cslbehring.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.